ReviewPharmaceuticals (Basel, Switzerland)2026
Mechanisms and Therapeutic Advances of Natural Products Regulating Non-Coding RNAs in Cancer.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, circular RNAs, tRNA-derived fragments, PIWI-interacting RNAs, and small nucleolar RNAs, have been identified as crucial regulators of gene expression and key drivers of cancer progression. Natural products, owing to their structural diversity and multi-targeting capacity, represent a promising reservoir for anticancer drug discovery through the modulation of these ncRNA networks. This review provides a comprehensive overview of the regulatory roles of natural products on ncRNAs in cancer. Compared with previous reviews that focus on individual ncRNA classes or single natural product categories, this review provides an integrated framework linking ncRNA biology, natural product pharmacology, and therapeutic delivery in cancer. First, the biogenesis, classification, and molecular functions of major ncRNA classes are systematically described, and the dysregulation of each ncRNA class across various cancer types and their contributions to tumor pathogenesis are then discussed. Subsequently, the modulation of these ncRNA networks by representative natural products, including polyphenols, flavonoids, terpenoids, and alkaloids, to influence multiple hallmarks of tumor progression, encompassing cell proliferation, programmed cell death, metastatic dissemination, tumor microenvironment remodeling, and therapeutic resistance, is reviewed. The potential of ncRNAs as diagnostic, prognostic, and pharmacodynamic biomarkers in the context of natural product-based therapy is discussed, together with emerging nanoparticle-based delivery strategies for co-delivering natural products and ncRNA therapeutics; however, most of the evidence summarized here remains preclinical, and clinical translation will require rigorous pharmacological and clinical validation. Finally, we address current challenges and future perspectives for the clinical translation of natural product-ncRNA-based anticancer strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.